Citadel Advisors
FDMT icon

Citadel Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Citadel Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Buy
23,700
+8,000
+51% +$69.6K ﹤0.01% 11210
2025
Q4 		$118K Buy
15,700
+3,100
+25% +$31.4K ﹤0.01% 11511
2025
Q3 		$109K Sell
12,600
-25,200
-67% -$151K ﹤0.01% 11787
2025
Q2 		$140K Buy
37,800
+4,900
+15% +$17.2K ﹤0.01% 11019
2025
Q1 		$106K Buy
32,900
+200
+0.6% +$942 ﹤0.01% 11369
2024
Q4 		$182K Sell
32,700
-2,100
-6% -$16.5K ﹤0.01% 10599
2024
Q3 		$376K Buy
34,800
+24,500
+238% +$407K ﹤0.01% 8837
2024
Q2 		$216K Buy
10,300
+5,800
+129% +$145K ﹤0.01% 9767
2024
Q1 		$143K Sell
4,500
-1,600
-26% -$40.8K ﹤0.01% 10827
2023
Q4 		$124K Buy
6,100
+700
+13% +$9.21K ﹤0.01% 10669
2023
Q3 		$68.7K Sell
5,400
-6,600
-55% -$110K ﹤0.01% 11342
2023
Q2 		$217K Buy
12,000
+600
+5% +$11K ﹤0.01% 9710
2023
Q1 		$196K Buy
11,400
+2,000
+21% +$38.9K ﹤0.01% 10219
2022
Q4 		$209K Buy
+9,400
New +$145K ﹤0.01% 10054
2022
Q1 		– Sell
-9,800
Closed -$215K – 13885
2021
Q4 		$215K Buy
+9,800
New +$240K ﹤0.01% 11694

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's FDMT Position: Q1 2026 in Review

Citadel Advisors increased its 4D Molecular Therapeutics (FDMT) stake by 1,228% in Q1 2026, buying an estimated $2.13M and bringing the position to 264,096 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5660.

Citadel Advisors first reported a position in FDMT in Q4 2020 and has held it in 20 quarters since. The position peaked at $3.37M in Q4 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Citadel Advisors held 264,096 shares of 4D Molecular Therapeutics worth $2.46M as of Q1 2026.
  • Citadel Advisors bought 244,207 4D Molecular Therapeutics shares in Q1 2026, an estimated $2.13M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5660 holding.
  • Citadel Advisors first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Citadel Advisors's 4D Molecular Therapeutics position peaked at $3.37M in Q4 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.